查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1808925

病毒載體合約開發製造組織市場，按載體類型、按工作流程階段、按規模、按應用、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Viral Vector Contract Development Manufacturing Organizations Market, By Vector Type, By Workflow Stage, By Scale, By Application, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 378 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

病毒載體合約開發製造組織市場規模在 2024 年價值 11.23 億美元，從 2025 年到 2032 年的複合年成長率為 18.5%。

病毒載體合約開發與製造組織 (CDMO) 市場專注於為基因療法、疫苗和細胞療法中使用的病毒載體生產提供外包服務。到 2024 年中期，全球將有超過 30 個基因療法獲批，並且腺相關病毒 (AAV)、慢病毒和腺病毒載體試驗的管道不斷擴大，這正在推動對專業化生產的需求。製藥和生物技術公司不斷增加的投資正在推動 CDMO 擴張，例如賽默飛世爾科技 (Thermo Fisher Scientific) 將在 2023 年投資 6.5 億美元，以擴展其細胞和基因治療網路。然而，高昂的生產成本、複雜的生物加工以及對病毒安全性和一致性的監管審查可能會阻礙其發展。儘管如此，透過戰略合作夥伴關係、平台標準化以及缺乏國內載體生產的地區不斷成長的需求，機會正在湧現。

病毒載體合約開發製造組織市場-市場動態

基因治療產品線的拓展和生物技術投資加速病毒載體CDMO市場的成長

基因治療產品線的快速擴張和生物技術投資的增加正在加速病毒載體CDMO市場的成長。根據美國FDA和再生醫學聯盟的數據，截至2024年，全球有超過2,000項基因治療臨床試驗正在進行中。這種激增促使主要製藥公司將載體生產外包給專門的CDMO，以滿足可擴展性和合規性需求。 2023年，美國生物醫學高級研究與發展管理局（BARDA）撥款擴大國內病毒載體生產，以減少對海外供應的依賴。 Catalent和賽默​​飛世爾科技等公司已投資數億美元用於增強病毒載體基礎設施，以滿足腫瘤學和罕見疾病治療對AAV和慢病毒載體日益成長的需求。這些發展突顯了在北美和歐洲建立長期CDMO合作夥伴關係和策略性產能擴張的明顯趨勢。

病毒載體合約開發製造組織市場-關鍵見解

根據我們的研究分析師的分析，預計全球市場在預測期內（2025-2032 年）的年複合成長率約為 18.5%。

根據載體類型細分，預計腺相關病毒 (AAV) 將在 2024 年佔據最大市場佔有率

根據工作流程階段細分，上游處理是 2024 年領先的工作流程階段

根據量表細分，臨床量表是2024年領先的量表

按地區分類，北美是 2024 年的主要收入來源

病毒載體合約開發製造組織市場區隔分析：

全球病毒載體合約開發製造組織市場根據載體類型、工作流程階段、規模、應用和地區進行細分。

根據載體類型，市場分為六類：腺病毒、慢病毒、腺相關病毒、逆轉錄病毒、單純皰疹病毒、雜交/嵌合載體。腺相關病毒 (AAV) 因其在基因傳遞方面的安全性和效率而處於領先地位，其次是慢病毒，因其穩定的基因整合能力而佔據主導地位。腺病毒在疫苗開發中排名第三，而逆轉錄病毒、單純皰疹病毒和雜交載體則用於利基療法。

根據工作流程階段，市場可分為兩類：上游處理（細胞培養（HEK293、Sf9）、轉染/感染方案）和下游處理（過濾和層析、超速離心、最終產品製劑）。上游處理佔據優先地位，其中HEK293細胞培養和最佳化的轉染方案廣泛用於可擴展的載體生產。其次是下游處理，其中過濾和層析主要用於純化，而超速離心和最終製劑對於確保載體穩定性和臨床級品質至關重要。

病毒載體合約開發製造組織市場-地理洞察

北美在病毒載體CDMO市場佔據領先地位，得益於其強大的生物製藥生態系統、政府資金和先進的基礎設施。 2023年，賽默飛世爾科技擴建了位於馬裡蘭州的工廠，以提高AAV載體的生產能力，同時美國FDA繼續加速基因療法的批准。歐洲也是一個重要的樞紐，德國、英國和荷蘭對合約生產的需求不斷成長。 2024年6月，Catalent與Oxford Biomedica合作，為歐洲客戶擴大病毒載體的生產規模。同時，以中國、日本和韓國為首的亞太地區正快速崛起，這些地區政府對細胞和基因治療的支持力度不斷加大，促使當地CDMO提升產能。 2024年，日本AGC Biologics宣布與當地基因治療公司建立策略夥伴關係，在千葉建立病毒載體生產線，標誌著該地區產能的增強。

病毒載體合約開發製造組織市場-競爭格局：

病毒載體CDMO市場呈現領導企業策略佈局與產能擴張的態勢。賽默飛世爾科技（Thermo Fisher Scientific）引領市場，於2019年收購了Brammer Bio，並於2021年1月以約7.25億歐元（約合8.75億美元）收購了諾華賽普（Novasep）旗下的Henogen部門，顯著增強了其在歐洲的病毒載體和劍橋業務。 Catalent在過去十年中支持了超過一半的FDA批准新藥，並在50多家工廠每年生產約700億劑藥物。諾和諾德（Novo Holdings）於2024年12月以165億美元收購了Catalent，重塑了藥物、基因治療和注射給藥領域的合約生產格局。區域合作進一步加劇了競爭，例如Catalent與Sarepta Therapeutics以及多家新冠疫苗製造商的合作。這些併購和聯盟策略共同展現了其透過規模化、全球覆蓋和治療專業化來增強差異化的優勢。

最新動態：

2025年6月，ProBio在新澤西州霍普韋爾開設了一座佔地12.8萬平方英尺的GMP工廠，用於生產質粒DNA和病毒載體。該廠將於2025年第三季開始生產AAV，並於2026年第一季開始提供LVV服務。

2024 年 5 月，Charles River Laboratories 啟動了一項病毒載體技術轉移計劃，提供兩個框架——用於無縫轉移的快速通道和用於可客製化應用的模組化——以便在短短 9 個月內加速向其馬裡蘭卓越中心的流程交接。

2024年9月，Rentschler Biopharma在其位於英國史蒂夫尼奇的先進療法工廠推出了一套全面的慢病毒載體 (LVV) 生產工具箱，以補充其現有的AAV服務。這套工具箱包括製程開發、cGMP 生產以及免版稅的 HEK293細胞株，以加速 ATMP 的生產。

目錄

第1章：病毒載體合約開發製造組織市場概覽

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 病毒載體合約開發製造組織市場片段（按載體類型）
    • 病毒載體合約開發製造組織市場片段（依工作流程階段）
    • 病毒載體合約開發製造組織市場片段（按規模）
    • 病毒載體合約開發製造組織市場片段（按應用）
    • 病毒載體合約開發製造組織市場片段（按國家/地區）
    • 病毒載體合約開發製造組織市場片段（按地區）
  • 競爭洞察

第3章：病毒載體合約開發製造組織關鍵市場趨勢

  • 病毒載體合約開發製造組織市場促進因素
    • 市場促進因素的影響分析
  • 病毒載體合約開發製造組織市場限制
    • 市場限制的影響分析
  • 病毒載體合約開發製造組織市場機會
  • 病毒載體合約開發製造組織市場未來趨勢

第4章：病毒載體合約開發製造組織產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：病毒載體合約開發製造組織市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：病毒載體合約開發製造組織市場格局

  • 病毒載體合約開發製造組織市場佔有率分析（2024年）
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：病毒載體合約開發製造組織市場 - 按載體類型

  • 概述
    • 按向量類型進行細分佔有率分析
    • 腺病毒
    • 慢病毒
    • 腺相關病毒
    • 逆轉錄病毒
    • 單純皰疹病毒
    • 雜交/嵌合載體

第8章：病毒載體合約開發製造組織市場－依工作流程階段

  • 概述
    • 依工作流程階段進行細分佔有率分析
    • 上游處理
      • 細胞培養（HEK293、Sf9）
      • 轉染/感染方案
    • 下游加工
      • 過濾和色譜法
      • 超速離心
      • 最終產品配方

第9章：病毒載體合約開發製造組織市場—依規模

  • 概述
    • 按規模細分市場佔有率分析
    • 臨床前（研發批次）
    • 臨床（I-III期）
    • 商業（市場供應）

第10章：病毒載體合約開發製造組織市場-按應用

  • 概述
    • 按應用細分市場佔有率分析
    • 基因治療
    • 癌症免疫療法
    • 傳染病疫苗
    • 罕見疾病治療

第 11 章：病毒載體合約開發製造組織市場-按地域

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 病毒載體合約開發製造組織北美主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測（按向量類型）
    • 北美市場規模與預測（按工作流程階段）
    • 北美市場規模及預測（按規模）
    • 北美市場規模和預測（按應用）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 病毒載體合約開發製造組織歐洲主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模和預測（按向量類型）
    • 歐洲市場規模與預測（按工作流程階段）
    • 歐洲市場規模及預測（按規模）
    • 歐洲市場規模和預測，按應用
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 病毒載體合約開發製造組織亞太地區主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依載體類型）
    • 亞太地區市場規模及預測（依工作流程階段）
    • 亞太地區市場規模及預測（依規模）
    • 亞太地區市場規模及預測（按應用）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 病毒載體合約開發製造組織拉丁美洲主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（依向量類型）
    • 拉丁美洲市場規模及預測（依工作流程階段）
    • 拉丁美洲市場規模及預測（按規模）
    • 拉丁美洲市場規模及預測（按應用）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 病毒載體合約開發製造組織中東和非洲的主要製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依載體類型）
    • MEA 市場規模與預測（依工作流程階段）
    • MEA 市場規模及預測（按規模）
    • MEA 市場規模及預測（按應用）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 12 章：關鍵供應商分析-病毒載體合約開發製造組織產業

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • AGC Biologics
    • Aldevron
    • Batavia Biosciences
    • BioReliance (Merck KGaA)
    • Catalent
    • Charles River Laboratories
    • Cobra Biologics (Charles River)
    • FUJIFILM Diosynth Biotechnologies
    • Genezen
    • iBET
    • Kaneka Eurogentec
    • Lonza
    • Novasep
    • Oxford Biomedica
    • REGENXBIO (CDMO Services arm)
    • Thermo Fisher Scientific (Patheon)
    • Vigene Biosciences (Charles River)
    • VIVEbiotech
    • WuXi Advanced Therapies
    • Yposkesi
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5543

Viral Vector Contract Development Manufacturing Organizations Market size was valued at US$ 1,123 Million in 2024, expanding at a CAGR of 18.5% from 2025 to 2032.

The Viral Vector Contract Development and Manufacturing Organizations (CDMO) Market focuses on outsourcing services for the production of viral vectors used in gene therapies, vaccines, and cell-based treatments. Over 30 gene therapy approvals globally by mid-2024 and an expanding pipeline of AAV, lentiviral, and adenoviral vector trials are fueling demand for specialized manufacturing. Rising investments from pharma and biotech firms are pushing CDMOs to scale up, with Thermo Fisher Scientific investing $650 million in 2023 to expand its cell and gene therapy network. However, high production costs, complex bioprocessing, and regulatory scrutiny over viral safety and consistency may restrain progress. Nonetheless, opportunities are emerging through strategic partnerships, platform standardization, and rising demand from regions lacking domestic vector production.

Viral Vector Contract Development Manufacturing Organizations Market- Market Dynamics

Expanding Gene Therapy Pipeline and Biotech Investments Accelerate Growth of Viral Vector CDMO Market

The rapid expansion of gene therapy pipelines and increased biotech investments are accelerating the growth of the viral vector CDMO market. As of 2024, over 2,000 gene therapy clinical trials are active globally, according to the U.S. FDA and Alliance for Regenerative Medicine. This surge has prompted major pharmaceutical players to outsource vector production to specialized CDMOs to meet scalability and compliance needs. In 2023, the U.S. Biomedical Advanced Research and Development Authority (BARDA) awarded funding to expand domestic viral vector manufacturing to reduce reliance on overseas supply. Companies like Catalent and Thermo Fisher Scientific have invested hundreds of millions to enhance viral vector infrastructure, addressing the rising demand for AAV and lentiviral vectors in oncology and rare disease therapies. These developments underscore a clear trend toward long-term CDMO partnerships and strategic capacity expansion across North America and Europe.

Viral Vector Contract Development Manufacturing Organizations Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 18.5% over the forecast period (2025-2032)

Based on Vector Type segmentation, Adeno-associated virus (AAV) was predicted to show maximum market share in the year 2024

Based on Workflow Stage segmentation, Upstream processing was the leading Workflow Stage in 2024

Based on Scale segmentation, the Clinical scale was the leading Scale in 2024

On the basis of region, North America was the leading revenue generator in 2024

Viral Vector Contract Development Manufacturing Organizations Market- Segmentation Analysis:

The Global Viral Vector Contract Development Manufacturing Organizations Market is segmented on the basis of Vector Type, Workflow Stage, Scale, Application, and Region.

The market is divided into six categories based on Vector Type: Adenovirus, Lentivirus, Adeno-associated Virus, Retrovirus, Herpes Simplex Virus, and Hybrid/Chimeric Vectors. Adeno-associated virus (AAV) leads due to its proven safety and efficiency in gene delivery, followed by lentivirus for stable gene integration. Adenovirus ranks third for vaccine development, while retrovirus, herpes simplex virus, and hybrid vectors are used in niche therapies.

The market is divided into two categories based on Workflow Stage: Upstream Processing (Cell culture (HEK293, Sf9), Transfection/infection protocols), and Downstream Processing (Filtration & Chromatography, Ultracentrifugation, Final Product Formulation). Upstream processing holds priority, with HEK293 cell culture and optimized transfection protocols widely used for scalable vector production. Downstream processing follows, where filtration and chromatography dominate purification, while ultracentrifugation and final formulation are essential for ensuring vector stability and clinical-grade quality.

Viral Vector Contract Development Manufacturing Organizations Market- Geographical Insights

North America holds a leading position in the viral vector CDMO market, supported by a robust biopharma ecosystem, government funding, and advanced infrastructure. In 2023, Thermo Fisher Scientific expanded its Maryland facility to enhance AAV vector production, while the U.S. FDA continued to accelerate approvals for gene therapies. Europe is also a key hub, with growing demand for contract manufacturing in Germany, the UK, and the Netherlands. In June 2024, Catalent collaborated with Oxford Biomedica to scale up viral vector manufacturing for European clients. Meanwhile, the Asia-Pacific region is emerging rapidly, led by China, Japan, and South Korea, where increasing government support for cell and gene therapy is prompting local CDMOs to boost capabilities. In 2024, Japan's AGC Biologics announced a strategic partnership with a local gene therapy company to establish viral vector production lines in Chiba, signaling regional capacity strengthening.

Viral Vector Contract Development Manufacturing Organizations Market- Competitive Landscape:

The viral vector CDMO market features strategic moves and capacity expansion among top players. Thermo Fisher Scientific leads the charge, acquiring Brammer Bio in 2019 and Novasep's Henogen division in January 2021 for approximatel €725 million (~$875 million), significantly enhancing its European viral vector footprint and complementing U.S. operations in Lexington, Cambridge, Plainville, and Alachua. Catalent-supporting over half of FDA-approved new drugs in the past decade and producing roughly 70 billion doses annually across 50+ facilities-was acquired by Novo Holdings for $16.5 billion in December 2024, reshaping contract manufacturing dynamics across drug, gene therapy, and injection delivery segments. Regional collaborations further enrich competition, such as Catalent's partnerships with Sarepta Therapeutics and multiple COVID-19 vaccine manufacturers. Together, these M&A and alliance strategies demonstrate intensifying differentiation through scale, global coverage, and therapeutic specialization.

Recent Developments:

In June 2025, ProBio opened a 128,000 sq ft GMP facility in Hopewell, New Jersey, to produce plasmid DNA and viral vectors. The site will begin AAV manufacturing by Q3 2025 and LVV services by Q1 2026.

In May 2024, Charles River Laboratories launched a viral vector tech transfer program, offering two frameworks-Fast Track for seamless transfers and Modular for customizable applications-to accelerate process handoffs to its Maryland Center of Excellence in as little as nine months.

In September 2024, Rentschler Biopharma launched a comprehensive lentiviral vector (LVV) manufacturing toolbox at its advanced therapies facility in Stevenage, UK, complementing its existing AAV services. This includes process development, cGMP manufacturing, and a royalty-free HEK293 cell line to accelerate ATMP production.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AGC Biologics
  • Aldevron
  • Batavia Biosciences
  • BioReliance (Merck KGaA)
  • Catalent
  • Charles River Laboratories
  • Cobra Biologics (Charles River)
  • FUJIFILM Diosynth Biotechnologies
  • Genezen
  • iBET
  • Kaneka Eurogentec
  • Lonza
  • Novasep
  • Oxford Biomedica
  • REGENXBIO (CDMO Services arm)
  • Thermo Fisher Scientific (Patheon)
  • Vigene Biosciences (Charles River)
  • VIVEbiotech
  • WuXi Advanced Therapies
  • Yposkesi
  • Others

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY VECTOR TYPE- MARKET ANALYSIS, 2019 - 2032

  • Adenovirus
  • Lentivirus
  • Adeno-associated Virus
  • Retrovirus
  • Herpes Simplex Virus
  • Hybrid/Chimeric Vectors

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY WORKFLOW STAGE- MARKET ANALYSIS, 2019 - 2032

  • Upstream Processing
  • Cell culture (HEK293, Sf9)
  • Transfection/infection protocols
  • Downstream Processing
  • Filtration & Chromatography
  • Ultracentrifugation
  • Final Product Formulation

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY SCALE- MARKET ANALYSIS, 2019 - 2032

  • Preclinical (R&D batches)
  • Clinical (Phase I-III)
  • Commercial (Market-ready supply)

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Gene Therapy
  • Cancer Immunotherapy
  • Infectious Disease Vaccines
  • Rare Disease Treatment

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Viral Vector Contract Development Manufacturing Organizations Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Vector Type
    • 2.1.2. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Workflow Stage
    • 2.1.3. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Scale
    • 2.1.4. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Application
    • 2.1.5. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Country
    • 2.1.6. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Region
  • 2.2. Competitive Insights

3. Viral Vector Contract Development Manufacturing Organizations Key Market Trends

  • 3.1. Viral Vector Contract Development Manufacturing Organizations Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Viral Vector Contract Development Manufacturing Organizations Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Viral Vector Contract Development Manufacturing Organizations Market Opportunities
  • 3.4. Viral Vector Contract Development Manufacturing Organizations Market Future Trends

4. Viral Vector Contract Development Manufacturing Organizations Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Viral Vector Contract Development Manufacturing Organizations Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Viral Vector Contract Development Manufacturing Organizations Market Landscape

  • 6.1. Viral Vector Contract Development Manufacturing Organizations Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Viral Vector Contract Development Manufacturing Organizations Market - By Vector Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Vector Type, 2024 & 2032 (%)
    • 7.1.2. Adenovirus
    • 7.1.3. Lentivirus
    • 7.1.4. Adeno-associated Virus
    • 7.1.5. Retrovirus
    • 7.1.6. Herpes Simplex Virus
    • 7.1.7. Hybrid/Chimeric Vectors

8. Viral Vector Contract Development Manufacturing Organizations Market - By Workflow Stage

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Workflow Stage, 2024 & 2032 (%)
    • 8.1.2. Upstream Processing
      • 8.1.2.1. Cell culture (HEK293, Sf9)
      • 8.1.2.2. Transfection/infection protocols
    • 8.1.3. Downstream Processing
      • 8.1.3.1. Filtration & Chromatography
      • 8.1.3.2. Ultracentrifugation
      • 8.1.3.3. Final Product Formulation

9. Viral Vector Contract Development Manufacturing Organizations Market - By Scale

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Scale, 2024 & 2032 (%)
    • 9.1.2. Preclinical (R&D batches)
    • 9.1.3. Clinical (Phase I-III)
    • 9.1.4. Commercial (Market-ready supply)

10. Viral Vector Contract Development Manufacturing Organizations Market - By Application

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 10.1.2. Gene Therapy
    • 10.1.3. Cancer Immunotherapy
    • 10.1.4. Infectious Disease Vaccines
    • 10.1.5. Rare Disease Treatment

11. Viral Vector Contract Development Manufacturing Organizations Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Viral Vector Contract Development Manufacturing Organizations Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AGC Biologics
    • 12.2.2. Aldevron
    • 12.2.3. Batavia Biosciences
    • 12.2.4. BioReliance (Merck KGaA)
    • 12.2.5. Catalent
    • 12.2.6. Charles River Laboratories
    • 12.2.7. Cobra Biologics (Charles River)
    • 12.2.8. FUJIFILM Diosynth Biotechnologies
    • 12.2.9. Genezen
    • 12.2.10. iBET
    • 12.2.11. Kaneka Eurogentec
    • 12.2.12. Lonza
    • 12.2.13. Novasep
    • 12.2.14. Oxford Biomedica
    • 12.2.15. REGENXBIO (CDMO Services arm)
    • 12.2.16. Thermo Fisher Scientific (Patheon)
    • 12.2.17. Vigene Biosciences (Charles River)
    • 12.2.18. VIVEbiotech
    • 12.2.19. WuXi Advanced Therapies
    • 12.2.20. Yposkesi
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us